ERBB2 and breast cancer: This German Breast Group’s study was a non-comparative randomized phase II trial investigating the pCR rate after neoadjuvant chemotherapy, with low-dose OLA (100 mg BID, continuously 12 weeks) administered concomitantly with weekly paclitaxel ×12, followed by EC ×4 in 69 patients with gBRCA1/2m, or somatic BRCA1/2 mutation, or a high homologous recombination deficiency (HRD) score (as defined by genome-wide copy number analysis on tumor DNA) and HER2-negative BC.